Oral membrane with PVA-TRIS buffer layer
By using a TRIS-PVA composition in oral films, the problem of PVA precipitation at high salt concentrations is solved, achieving high optical uniformity and wide pH adjustment, simplifying the production of multilayer films, and making them suitable for drug delivery and pH stabilization.
Patent Information
- Application Number
- CN202280010134.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2021-01-15
- Filing Date
- 2022-01-14
- Publication Date
- 2026-11-17
- Estimated Expiration
- 2042-01-14
AI Technical Summary
Polyvinyl alcohol (PVA) is prone to precipitation or clumping at high salt concentrations, making it difficult to process oral films uniformly at high buffer concentrations. This affects the coating appearance and pH adjustment effect. Furthermore, existing technologies cannot simultaneously achieve easy processing, foaming, and high optical uniformity in oral films.
The oral film uses polyvinyl alcohol and tris(hydroxymethyl)aminomethane (TRIS). By adding a high proportion of TIS as a buffer, a film with high optical uniformity is formed. Multilayer films are produced by lamination technology without the need for other adhesives, and can be adapted to a wide pH range.
It achieves the goal of preventing PVA precipitation and clumping at high buffer concentrations, ensuring the uniformity and pH adjustment capability of oral films, while simplifying the production process of multilayer films, making it suitable for drug delivery and pH stabilization.
Smart Images

Figure CN116782880B_ABST
Abstract
Description
[0001] This invention relates to oral films (also abbreviated as OTF) comprising at least one layer containing at least one polyvinyl alcohol and tris(hydroxymethyl)aminomethane, and to the use of such oral films as pharmaceuticals.
[0002] Polyvinyl alcohol (PVA) is a well-known and widely used matrix polymer for oral films because it is well-suited as a matrix polymer for foam formulations or other film-like OTF formulations. However, PVA can only be processed well in solutions with low ionic strength. At high salt concentrations, such as high buffer concentrations, PVA easily precipitates or clumps. A uniform coating appearance then becomes impossible. For many applications, such as adjusting the pH of oral saliva to an optimal level for surfactant penetration and oral hygiene, the use of stronger buffers, i.e., higher buffer concentrations, is necessary to adjust or maintain a specific pH in saliva, which is advantageous for, for example, continuous surfactant absorption.
[0003] The object of this invention is to overcome the aforementioned disadvantages of the prior art. In particular, the object of this invention is to provide an oral film comprising PVA and containing as many as possible of at least one buffering substance, while simultaneously ensuring that the formulation is easy to process and that the PVA does not precipitate and / or clump. At the same time, it is desirable to find a formulation that can foam well and form a film with the highest possible optical homogeneity. Furthermore, the oral film should allow adjustment of the pH value in the patient's saliva within the widest possible range, while also being as stable as possible. For this purpose, it should be possible to incorporate as many buffering substances as possible into the PVA.
[0004] In addition, oral films should be as easy to manufacture as possible, and multi-layer oral films should be constructed as simply as possible.
[0005] The above objective is achieved by a multilayer oral film according to claim 1, and in particular by an oral film comprising at least one layer containing at least one polyvinyl alcohol and tris(hydroxymethyl)aminomethane (TRIS).
[0006] The oral film, which includes at least one layer containing at least one polyvinyl alcohol and tris(hydroxymethyl)aminomethane (TRIS), will also be referred to below as the TRIS-PVA layer or the TRIS buffer layer.
[0007] The advantage of such oral films is that TRIS can be incorporated into the highest proportion of buffer / PVA in both percentage and molar amounts. On the other hand, PVA can clump or precipitate when combined with other salts / buffers (phosphates, carbonates, citric acid, etc.).
[0008] TRIS-PVA compositions can be well foamed and form films with high optical uniformity.
[0009] Layers with very high TRIS loadings can also be produced, preferably with a TRIS content as high as 50 wt%. Furthermore, a wider pH range can be covered by adjustment with an acid (e.g., hydrochloric acid). Another advantage is that, in some embodiments, these oral films can be laminated together without additional adhesives, i.e., relatively thick multilayer films can be produced by laminating multiple layers of TRIS-PVA together. The TRIS buffer layer can be co-administered with an OTF containing the active ingredient to maintain a suitable pH in the oral cavity. This can be achieved by sequentially administering the TRIS buffer layer and the active ingredient OTF (or vice versa), or by combining the TRIS buffer layer with the active ingredient layer (e.g., laminating to form a multilayer OTF), or by the TRIS buffer layer itself containing at least one pharmaceutically active ingredient. In particular, using ketamine as the pharmaceutically active ingredient can create a system beneficial for clinical reproducibility (compensating for fluctuations in oral / saliva pH) and buffering the oral cavity to a pH favorable for osmosis.
[0010] Here, "contains" can also mean "composed of".
[0011] TRIS is an abbreviation for tris(hydroxymethyl)aminomethane (THAM), also known as tromethamine, thromboxane (INN), and TRIS buffer. Chemically, it is a primary amine with three hydroxyl groups.
[0012] TRIS is used as a buffer in biochemistry, molecular biology, microbiology, and pharmaceuticals. TRIS has a pKs of 8.2 (at 20°C) and exhibits good buffering capacity between pH 7.2 and 9.0.
[0013] Polyvinyl alcohol (abbreviated as PVA or PVAL, sometimes also called PVOH) is a polymer with the following general structure.
[0014]
[0015] A small percentage (approximately 2%) may also contain the following types of structural units.
[0016]
[0017] They belong to the vinyl polymer group.
[0018] Commercially available polyvinyl alcohol (PVA) is supplied as a white-yellow powder or granular material with a degree of polymerization between approximately 500 and 2500 (molar mass approximately 20,000 to 100,000 g / mol) and a degree of hydrolysis typically between 98 and 99 mol%, or 87 to 89 mol%, meaning they still contain residual acetyl groups. Manufacturers determine the properties of PVA by specifying the degree of polymerization, degree of hydrolysis, saponification number, and / or solution viscosity of the starting polymer.
[0019] According to the present invention, polyvinyl alcohol with an average molecular weight of about 31,000 (4-88) to about 205,000 (40-88) g / mol is particularly suitable.
[0020] Furthermore, according to the present invention, polyvinyl alcohol with a viscosity of 3.4-4.6 mPas (4-88) to 34-46 mPas (40-88) mPas, as determined by the falling ball method (Ph.Eur.2.2.49), or a mixture of two or more different types of PVA, is particularly suitable in an aqueous solution of 40 g / L.
[0021] A preferred feature of the oral film according to the invention is that, relative to the total weight of at least one layer, the content of polyvinyl alcohol in at least one layer is 20 to 90 wt%, preferably 40 to 80 wt%, and particularly preferably 50 to 75 wt%.
[0022] Another preferred feature of the oral film according to the invention is that, relative to the total weight of at least one layer, the content of polyvinyl alcohol in at least one layer is 20 to 50 wt%, preferably 25 to 45 wt%, and particularly preferably 30 to 40 wt%.
[0023] Another preferred feature of the oral film according to the invention is that, relative to the total weight of at least one layer, the content of polyvinyl alcohol in at least one layer is 60 to 85 wt%, preferably 65 to 80 wt%, and particularly preferably 65 to 75 wt%.
[0024] A further preferred feature of the oral film according to the invention is that the content of tris(hydroxymethyl)aminomethane in at least one layer is 3 to 70 wt%, preferably 10 to 55 wt%, and very particularly preferably 15 to 50 wt%, relative to the total weight of at least one layer.
[0025] Another preferred feature of the oral film according to the invention is that, relative to the total weight of at least one layer, the content of tris(hydroxymethyl)aminomethane in at least one layer is 10 to 50 wt%, or 15 to 45 wt%, or 15 to 40 wt%.
[0026] Another preferred feature of the oral film according to the invention is that, relative to the total weight of at least one layer, the content of tris(hydroxymethyl)aminomethane in at least one layer is 20 to 55 wt%, or 20 to 50 wt%, or 20 to 45 wt%, or 20 to 40 wt%.
[0027] Another preferred feature of the oral film according to the invention is that, relative to the total weight of at least one layer, the content of tris(hydroxymethyl)aminomethane in at least one layer is 25 to 55% by weight, or 25 to 50% by weight, or 25 to 45% by weight, or 25 to 40% by weight.
[0028] Another preferred feature of the oral film according to the invention is that, relative to the total weight of at least one layer, the content of tris(hydroxymethyl)aminomethane in at least one layer is about 15% by weight, or about 16.7% by weight, or about 25% by weight, or about 25.5% by weight, or about 40% by weight, or about 50% by weight.
[0029] Preferably, the oral film according to the invention does not contain any buffering substances other than TRIS, and in particular does not contain phosphates, carbonates and / or citric acid.
[0030] A further preferred feature of the oral film according to the invention is that it does not contain any buffering substances other than TRIS in at least one layer containing at least one polyvinyl alcohol and tris(hydroxymethyl)aminomethane (TRIS), particularly not phosphates, carbonates and / or citric acid.
[0031] Preferably, at least one layer containing at least one polyvinyl alcohol and tris(hydroxymethyl)aminomethane (TRIS) does not contain polymers other than PVA.
[0032] A further preferred feature of the oral film according to the invention is that at least one layer contains at least one pharmaceutically active substance.
[0033] In embodiments of the oral film according to the present invention, it is conceivable that the oral film does not contain pharmaceutically active substances and is used only as a "buffer film".
[0034] At least one pharmaceutically active substance is not subject to any restrictions in principle, but is preferably selected from all pharmaceutically active substances suitable for oral and / or mucosal administration.
[0035] According to the present invention, the pharmaceutically active substance also includes all pharmaceutically acceptable salts and solvates relating to the pharmaceutically active substance.
[0036] Preferred pharmaceutically active substances are selected from pharmaceutically active substances comprising the following group: analgesics, hormones, hypnotics, sedatives, antiepileptics, analgesics, psychotropic drugs, neuromuscular blocking agents, anticonvulsants, antihistamines, antiallergics, cardiotonics, antiarrhythmics, diuretics, antihypertensives, vasopressors, antidepressants, antitussives, expectorants, thyroid hormones, sex hormones, antidiabetic agents, antitumor active agents, antibiotics, chemotherapeutic agents, and anesthetics, although this group is not exhaustive.
[0037] According to the present invention, at least one pharmaceutically active substance is ketamine and / or a pharmaceutically acceptable salt thereof, preferably including ketamine hydrochloride.
[0038] In this paper, ketamine is understood as (S)-(±)-2-(2-chlorophenyl)-2-(methylamino)cyclohexane-1-one, (R)-(±)-2-(2-chlorophenyl)-2-(methylamino)cyclohexane-1-one, and the racemic (RS)-(±)-2-(2-chlorophenyl)-2-(methylamino)cyclohexanone-1-one.
[0039] (S)-ketamine or a pharmaceutically acceptable salt thereof, particularly (S)-ketamine hydrochloride, is particularly preferred as a single stereoisomer of ketamine because (S)-ketamine has approximately three times the analgesic and anesthetic potency of (R)-ketamine.
[0040] The surfactant content in at least one layer can vary over a relatively wide range. A content range of 10 to 60 wt% relative to the dry weight of at least one layer is considered suitable. In another embodiment, the surfactant content in at least one layer tends to be in the range of 25 to 35 wt%, or 25 to 45 wt%, or 25 to 55 wt%.
[0041] A further preferred feature of the oral film according to the invention is that the at least one layer contains at least one auxiliary substance selected from colorants, flavoring agents, sweeteners, plasticizers, masking agents, emulsifiers, reinforcing agents, humectants, preservatives and / or antioxidants.
[0042] Each of these auxiliary substances is preferably contained in at least one layer, and its content is from 0.1 to 40 wt%, preferably from 0.1 to 30 wt%, particularly preferably from 0.1 to 15 wt%, very particularly preferably from 0.1 to 10 wt%, or from 0.1 to 5 wt%, relative to the total weight of the layer.
[0043] After drying or solvent removal, it is preferable that the residual solvent content in the oral film is in the range of 0.2 to 15 wt%, more preferably in the range of 0.8 to 7 wt%, relative to the total weight of the oral film.
[0044] Preferably, the oral film has at least one additional layer comprising at least one matrix polymer and at least one pharmaceutically active substance.
[0045] In this case, the oral membrane is therefore a multilayer oral membrane.
[0046] At least one layer comprising at least one polyvinyl alcohol and tris(hydroxymethyl)aminomethane may contain at least one pharmaceutically active substance, or in another embodiment, may not contain a pharmaceutically active substance.
[0047] If at least one layer containing at least one polyvinyl alcohol and tris(hydroxymethyl)aminomethane does not contain a pharmaceutically active substance, then preferably at least one pharmaceutically active substance is contained in at least one of the other layers.
[0048] In this case, at least one layer containing at least one polyvinyl alcohol and tris(hydroxymethyl)aminomethane serves only as a buffer layer to adjust the ideal pH value in the patient's oral cavity.
[0049] The oral film according to the invention has at least one other layer comprising at least one matrix polymer and at least one pharmaceutically active substance, preferably characterized in that the at least one polymer is a water-soluble polymer selected from the group consisting of: starch and starch derivatives, dextrin, cellulose derivatives such as carboxymethyl cellulose, hydroxypropyl cellulose, hydroxyethyl cellulose, hydroxypropyl methyl cellulose, hydroxypropyl ethyl cellulose, sodium carboxymethyl cellulose, ethyl or propyl cellulose, polyacrylic acid, polyacrylate, polyvinylpyrrolidone, vinylpyrrolidone / vinyl acetate copolymer, polyvinyl alcohol, polyethylene oxide polymer, polyacrylamide, polyethylene glycol, gelatin, collagen, alginate, pectin, pullulan, astragalus gum, chitosan, alginic acid, arabinogalactan, galactomannan, agar, agarose, carrageenan, and natural gums.
[0050] At least one pharmaceutically active substance is not subject to any restrictions in principle, but is preferably selected from all pharmaceutically active substances suitable for oral and / or mucosal administration.
[0051] All the active agents mentioned also include their pharmaceutically acceptable salts and / or solvates.
[0052] The oral film according to the invention has at least one other layer comprising at least one matrix polymer and at least one pharmaceutically active substance, preferably characterized in that the at least one pharmaceutically active substance is selected from pharmaceutically active substances comprising the group consisting of: analgesics, hormones, hypnotics, sedatives, antiepileptics, analgesics, psychotropic drugs, neuromuscular blocking agents, antispasmodics, antihistamines, antiallergics, cardiotonics, antiarrhythmics, diuretics, antihypertensives, vasopressors, antidepressants, antitussives, expectorants, thyroid hormones, sex hormones, antidiabetic agents, antitumor active agents, antibiotics, chemotherapeutic agents, and anesthetics, wherein the at least one pharmaceutically active substance preferably comprises ketamine, and particularly preferably comprises (S)-ketamine.
[0053] In one embodiment, the multilayer oral film according to the invention is characterized in that at least one layer comprising at least one polyvinyl alcohol and tris(hydroxymethyl)aminomethane, and / or at least one other layer comprising at least one matrix polymer and at least one pharmaceutically active substance, are directly laminated to each other.
[0054] In another embodiment, the multilayer oral film according to the invention is characterized in that at least one layer comprising at least one polyvinyl alcohol and tris(hydroxymethyl)aminomethane, and / or at least one other layer comprising at least one matrix polymer and at least one pharmaceutically active substance or at least one flavoring agent, are bonded to each other by an intermediate adhesive layer.
[0055] An adhesive layer is a layer that can be used as an adhesive as defined in DIN EN 923:2016-03. Therefore, non-adhesive layers cannot be used as adhesives as defined above.
[0056] Suitable adhesive coatings are, in particular, water-soluble adhesive coatings as described in DE 10 2014 127 452 A1, the contents of which are incorporated herein by reference.
[0057] Such adhesive layers comprise at least one water-soluble polymer and at least one plasticizer, wherein the at least one water-soluble polymer in the at least one water-soluble adhesive layer preferably includes shellac, polyvinylpyrrolidone / vinyl acetate copolymer, polyvinylcaprolactam / polyvinyl acetate / polyethylene glycol copolymer, hydroxypropyl cellulose or hydroxypropyl methylcellulose and / or polyvinylpyrrolidone, and wherein the at least one plasticizer in the at least one water-soluble adhesive layer preferably includes glycerol, polyethylene glycol, particularly polyethylene glycol 200, and / or tributyl citrate.
[0058] In at least one adhesive layer, the weight ratio of at least one water-soluble polymer to at least one plasticizer is preferably from about 90 to 50 to about 10 to 50, and more preferably from about 85 to 50 to about 15 to 50.
[0059] This adhesive layer, containing at least one water-soluble polymer and at least one plasticizer, can serve as an intermediate water-soluble adhesive layer, firmly bonding two other non-adhesive layers together. This allows for the construction of multi-layer oral films without the need for multiple coating operations, which would otherwise require increased drying time and increased temperature and pressure on the active agents and excipients.
[0060] In another embodiment, the multilayer oral film according to the invention is characterized in that at least one layer comprising at least one polyvinyl alcohol and tris(hydroxymethyl)aminomethane, and / or at least one other layer comprising at least one matrix polymer and at least one pharmaceutically active substance or at least one flavoring agent are bonded to each other through an intermediate separating layer.
[0061] Preferably, a layer containing at least one polyethylene glycol is used as a separation layer.
[0062] Polyethylene glycol (PEG) is a compound with the general formula:
[0063]
[0064] Polyethylene glycol (melting temperature approximately 65°C) is also commonly referred to as polyethylene oxide or polyoxyethylene (abbreviated as PEO or less commonly PEOX) or polywax. In this document, the terms "polyethylene glycol," "polyethylene oxide," and "polyoxyethylene" are used interchangeably.
[0065] At least one polyethylene glycol preferably has an average molecular weight of at least 20,000 g / mol to 7,000,000 g / mol, more preferably 40,000 g / mol to 500,000 g / mol, particularly preferably 95,000 g / mol to 105,000 g / mol, especially about 100,000 g / mol.
[0066] The molecular weight is obtained from the rheological measurements described below.
[0067] At least one polyethylene glycol preferably has a viscosity of 30 mPas to 50 mPas, measured at 25°C.
[0068] The viscosity mentioned in each case refers to a 5 wt% polyethylene glycol solution and was measured on a Brookfield viscometer (model RVF) with spindle No. 1, a rotation speed of 50 rpm, and a temperature of 25°C.
[0069] Polyethylene glycol traded under the name POLYOX WSR N-10 (Dow Chemical) is particularly preferred.
[0070] The content of at least one polyethylene glycol in at least one separation layer is preferably 60 to 100 wt%, more preferably 80 to 100 wt%, relative to the total weight of at least one separation layer.
[0071] The separating layer preferably contains at least one plasticizer, preferably glycerin, in an amount preferably from 0.5 to 5 wt% relative to the total weight of at least one separating layer, particularly preferably from 2 to 2.5 wt%.
[0072] One advantage of using this type of separation layer is that polyethylene glycol (PEG) membranes, due to their smooth surface, low melting point or glass transition temperature, safe toxicity, and water solubility, are ideally suited as separation / connecting / adhesive layers in multilayer oral films. PEG adhesive layers are particularly suitable for bonding other two layers together when heated and / or pressurized. For example, a layer containing active ingredients and a pH-regulating buffer layer can be bonded together.
[0073] In addition, polyethylene glycol layers are suitable as barrier layers to prevent or minimize the migration of surfactants or auxiliary substances (such as buffer salts) between layers.
[0074] The separation layer requires little or no auxiliary substances, such as plasticizers (e.g., 2-3% glycerin), thus reducing the risk of adhesive layer components migrating to other layers of the oral film.
[0075] The multilayer oral film according to the present invention is not limited in structure.
[0076] Therefore, it is conceivable that the multilayer oral film comprises a TRIS buffer layer without pharmaceutically active substances and other layers containing at least one matrix polymer and at least one pharmaceutically active substance.
[0077] These two layers can be laminated together directly, or they can be bonded together using an intermediate adhesive layer or a release layer as defined above.
[0078] It is also conceivable that a multilayer oral membrane consists of a TRIS buffer layer without pharmaceutically active substances and other layers containing at least one matrix polymer and at least one pharmaceutically active substance.
[0079] These two layers can be laminated together directly, or they can be bonded together using an intermediate adhesive layer as defined above.
[0080] An embodiment of a multilayer oral film is also conceivable, wherein the multilayer oral film comprises a TRIS buffer layer without a pharmaceutically active substance and other layers containing at least one matrix polymer and at least one pharmaceutically active substance, the two layers being bonded together by an adhesive layer or a release layer as defined above.
[0081] An embodiment of a multilayer oral film is also conceivable, wherein the multilayer oral film consists of a TRIS buffer layer without pharmaceutically active substances and other layers containing at least one matrix polymer and at least one pharmaceutically active substance, the two layers being bonded together by an adhesive layer or a release layer as defined above.
[0082] Other multilayer oral films are conceivable, for example, having the following layer structure: a TRIS buffer layer - a layer containing at least one matrix polymer and at least one pharmaceutically active substance - a TRIS buffer layer.
[0083] In this implementation, two TRIS buffer layers form the outer side of a multilayer oral membrane.
[0084] These three layers can be laminated together directly, or they can be bonded to an intermediate adhesive layer, preferably as defined above.
[0085] In principle, a modular system can be provided; more specifically, any arrangement of the TRIS buffer layer and other layers can be provided.
[0086] In all the embodiments described above, the TRIS buffer layer preferably does not contain any pharmaceutically active substance. However, embodiments in which each TRIS buffer layer in a multilayer film contains at least one pharmaceutically active substance are also conceivable.
[0087] A further preferred feature of the oral film according to the invention is that at least one layer comprising at least one polyvinyl alcohol and tris(hydroxymethyl)aminomethane and / or at least one other layer comprising at least one matrix polymer and at least one pharmaceutically active substance exists in the form of a coagulated foam having cavities.
[0088] The cavities of the membrane and the associated large surface area are particularly conducive to the entry of water, saliva, or other bodily fluids into the interior of the dosage form, thereby accelerating the dissolution of the dosage form and the release of the active substance.
[0089] In cases of rapid absorption of surfactants, absorption via the mucosa can also be improved through rapid dissolution of the matrix layer. On the other hand, the wall thickness of the cavities is preferably small, because these cavities represent solidified bubbles, for example, so that rapid dissolution or destruction of these cavities can occur.
[0090] Another advantage of this implementation is that, despite the relatively high surface weight, faster drying can be achieved by formulating it into a foam compared to comparable non-foam compositions.
[0091] A preferred feature of the oral film according to the invention is that the cavities are isolated from each other and preferably exist in the form of bubbles, the cavities being filled with air or gas, preferably an inert gas, particularly preferably nitrogen, carbon dioxide, helium, argon or a mixture of at least two of these gases.
[0092] According to another embodiment, these cavities are configured in an interconnected manner, preferably by forming a continuous channel system that penetrates the substrate.
[0093] The cavity preferably has a volume fraction of 5 to 98%, more preferably 50 to 80%, relative to the total volume of the layer. In this way, the desired effect of accelerating the dissolution of the surfactant-containing matrix layer is advantageously influenced.
[0094] In addition, surfactants or surface-active substances can be added to the matrix polymer or the polymer matrix used to form the foam, or to the foam obtained before or after drying, in order to improve the stability of the foam before or after drying.
[0095] Another parameter affecting the dosage form properties according to the invention is the diameter of the cavities or bubbles. The bubbles or cavities are preferably generated by means of a foaming machine, by which the diameter of the bubbles can be adjusted arbitrarily within a wide range. Therefore, the diameter of the bubbles or cavities can range from 1 to 350 micrometers. Particularly preferred is a diameter in the range of 30 to 200 micrometers.
[0096] The oral film according to the invention preferably has a diameter of 0.5 cm. 2 Approximately 10 cm 2 1.5 cm is particularly preferred. 2 Approximately 9 cm 2 The area.
[0097] A preferred feature of the oral film according to the invention is that the surface weight of the oral film is 10 to 500 g / m. 2 Preferred weight is 100 to 400 grams per meter. 2 .
[0098] The surface weight of the TRIS buffer layer and any other layers that may be present is preferably at least 10 g / m², more preferably at least 20 g / m², or at least 30 g / m², or most preferably at least 50 g / m², or less than or equal to 400 g / m², more preferably less than or equal to 350 g / m², or less than or equal to 300 g / m², or most preferably less than 250 g / m². Preferably, the surface weight is from 10 to 400 g / m², more preferably from 20 to 350 g / m², or 30 to 300 g / m², and most preferably from 50 to 250 g / m².
[0099] Preferably, the thickness of the TRIS buffer layer and any other layers that may be present is preferably from 10 micrometers to 500 micrometers, and particularly preferably from 20 micrometers to 300 micrometers.
[0100] If the TRIS buffer layer is in the form of foam, the thickness of the TRIS buffer layer is preferably 10 micrometers to 3000 micrometers, and particularly preferably 90 micrometers to 2000 micrometers.
[0101] A further preferred feature of the oral film according to the invention is that the oral film produces a pH value (at 37°C) of 6 to 9, preferably 6 to 8, in the oral cavity of a patient, preferably a human.
[0102] A further preferred feature of the oral film according to the invention is that the oral film produces a pH value (at 37°C) of 6 to 8 in 2 mL of human saliva, artificial saliva, PBS buffer, or water.
[0103] A further preferred feature of the oral film according to the invention is that the oral film comprises a TRIS buffer layer and another layer containing S-ketoamine hydrochloride, and produces a pH of 6 to 8 (at 37°C) in 2 ml of human saliva, artificial saliva, PBS buffer, or water.
[0104] A further preferred feature of the oral film according to the invention is that the oral film comprises a TRIS buffer layer and another layer containing 16.3 mg of S-ketamine hydrochloride, producing a pH of 6 to 8 (at 37°C) in 2 ml of human saliva, artificial saliva, PBS buffer, or water.
[0105] A further preferred feature of the oral film according to the invention is that the oral film comprises a TRIS buffer layer and another layer containing 32.2 mg of S-ketamine hydrochloride, producing a pH of 6 to 8 (at 37°C) in 2 ml of human saliva, artificial saliva, PBS buffer, or water.
[0106] The present invention also relates to a kit comprising at least one first oral film including at least one layer comprising at least one polyvinyl alcohol and tris(hydroxymethyl)aminomethane, and at least one second oral film comprising at least one matrix polymer and at least one pharmaceutically active substance, wherein the first and second oral films are preferably different. Preferably, in this kit, the first oral film does not contain a pharmaceutically active substance.
[0107] The above explanation of the TRIS buffer layer and other layers applies similarly to the first and second oral films present in the kit according to the invention.
[0108] The oral film according to the present invention can be produced according to methods known to those skilled in the art.
[0109] Known production methods involve providing a solution containing PVA and TIS, then unfolding and drying the solution to obtain a membrane.
[0110] When producing multilayer oral films, known manufacturing methods include: providing a first solution containing PVA and TIS, then spreading and drying the solution to obtain a film, and providing a second solution containing at least one matrix polymer and at least one pharmaceutically active substance to obtain a second film.
[0111] The bonding of these two membranes can, in principle, be accomplished using methods known to those skilled in the art. For example, the other membrane can be coated onto the first membrane; it is not important which membrane is coated onto which membrane. Furthermore, the two membranes can be bonded together using the aforementioned adhesive layer.
[0112] The present invention further relates to oral films that can be obtained by the above methods.
[0113] The present invention also relates to the oral film described above as a drug, which can be obtained by the above method or kit.
[0114] The present invention also relates to oral films, which are obtained as described above or by the methods or kits described above, wherein ketamine, preferably S-ketamine (optionally as a pharmaceutically acceptable salt or ion pair) is used as a pharmaceutically active agent for the treatment of pain and / or depression, particularly for reducing the risk of suicide and / or as a general anesthetic, preferably for initiating and administering general anesthesia, or as a supplement to local anesthesia and / or as an analgesic.
[0115] The invention will now be explained in more detail through some non-limiting embodiments. Example
[0116] Example 1:
[0117] Effect of pH on the permeability of (S)-ketamine hydrochloride
[0118] Acid buffers:
[0119] 80 g / L Na₂HPO₄x₂H₂O dissolves in water; at 22°C, the pH is adjusted to pH = 4.99 using a 1M HCl aqueous solution.
[0120] Neutral buffer solution:
[0121] 80 g / L Na₂HPO₄x₂H₂O dissolves in water; at 22°C, the pH is adjusted to pH = 7.46 using a 1M HCl aqueous solution.
[0122] Alkaline buffer solution:
[0123] 80 g / L Na₂HPO₄x₂H₂O dissolves in water; at 22°C, the pH is adjusted to 8.33 using a 1M HCl aqueous solution.
[0124] The pH values of this series of tests are summarized in Table 1.
[0125] Table 1:
[0126]
[0127] According to OECD guidelines (adopted April 13, 2004), the permeation rate of (S)-ketamine was determined in vitro using porcine mucosa (esophageal mucosa) and a "Franz diffusion cell". The mucosa was prepared to a thickness of 400 micrometers and a diameter of 1.145 cm using a membrane. 2 All transmucosal therapy systems maintain intact barrier function.
[0128] The receiving medium was 4 mL of PBS buffer, pH 7.4, at 37°C.
[0129] 2.77 mg of (S)-ketamine hydrochloride was applied to a mucosa, allowing the active agent-coated mucosa to contact the upper buffer solution. The lower side of the mucosa contacted the acceptor medium. The permeation of S-ketamine into the acceptor medium was measured at 37 ± 1 °C. The results showed... Figure 1 middle.
[0130] The osmotic results show that S-ketamine has the best osmotic rate in neutral buffer, followed by alkaline buffer. The osmotic rate is lowest in acidic buffer.
[0131] Example 2:
[0132] The effect of pH on the permeability of (S)-ketamine hydrochloride in oral films.
[0133] Oral films conforming to the composition in Table 2 were prepared.
[0134] Table 2:
[0135]
[0136] PVA 4-88: Polyvinyl alcohol
[0137] Flavoring: MANE Cherry M55394
[0138] Colorant: FD&C Red 40
[0139] The oral films with the formulation according to Table 2 are produced by mass production techniques known to those skilled in the art, such as by stirring / mixing the contained components using a stirring motor and suitable stirring tools.
[0140] Gas is injected into the resulting substance through stirring, for example, using a foaming machine.
[0141] Using appropriate equipment (roller applicator, scraper, application box, etc.), the foaming material is applied to the coating substrate at a constant layer thickness.
[0142] All temperature-stable mesh materials can serve as coating substrates from which the dry film can be removed again. This can be ensured by selecting the material of the coating substrate (the different surface tensions between the foam and the substrate) or by applying a suitable debonding coating to the coating substrate using materials such as silicone or fluoropolymers.
[0143] The process solvent or solvent contained therein is typically water or a mixture of water and an organic-aqueous miscible solvent, which is removed by drying. Oral films can be supplied in appropriate sizes by cutting or punching holes in the resulting solid foam layer.
[0144] Acid buffers:
[0145] 80 g / L Na₂HPO₄x₂H₂O dissolves in water; at 22°C, the pH is adjusted to pH = 4.99 using a 1M HCl aqueous solution.
[0146] Neutral buffer solution:
[0147] 80 g / L Na₂HPO₄x₂H₂O dissolves in water; at 22°C, the pH is adjusted to pH = 7.46 using a 1M HCl aqueous solution.
[0148] Alkaline buffer solution:
[0149] 80 g / L Na₂HPO₄x₂H₂O dissolves in water; at 22°C, the pH is adjusted to pH = 8.33 using a 1M HCl aqueous solution.
[0150] The pH values of this series of tests are summarized in Table 3.
[0151] Table 3:
[0152]
[0153] Place 0.287 square centimeters of S-ketamine hydrochloride formulation 1 OTF (equivalent to 2.77 mg (S)-ketamine) on the mucosa and add 70 μL of buffer solution.
[0154] The permeability measurement was similar to that in Example 1.
[0155] According to OECD guidelines (adopted April 13, 2004), the permeation rate of (S)-ketamine was determined in vitro using porcine mucosa (esophageal mucosa) and a "Franz diffusion pool". A membrane was used to prepare the mucosa to a thickness of 400 micrometers, ensuring the intact barrier function of all transmucosal treatment systems.
[0156] A 0.287 cm² perforation is punched out of the OTF and applied to the mucosa, ensuring that the upper side of the OTF-coated mucosa is in contact with the buffer solution (the lower side is in contact with the receiving medium), and the upper side is cut into 1.145 cm² pieces. 2 (mucosal area).
[0157] The permeation of S-ketamine in the receiving medium (phosphate buffer solution, pH 7.4) was measured at a temperature of 37±1℃. The results showed... Figure 2 middle.
[0158] In vitro experiments using different buffer solutions as donor media showed that the osmotic behavior of S-ketamine depends on the pH of the buffer solution used. The pH values of the donor media, including the surfactant, are shown in Table 2 (buffer solution + OTF).
[0159] The osmotic results show that S-ketamine has the best osmotic rate in alkaline buffers, followed by neutral buffers. Acidic buffers have the lowest osmotic rate.
[0160] Example 3:
[0161] Table 4:
[0162]
[0163]
[0164] PVA 4-88: Polyvinyl alcohol
[0165] PVA 40-88: Polyvinyl alcohol
[0166] Flavoring: MANE Cherry M55394
[0167] Colorant: FD&C Red 40
[0168] Aerosil 200: Hydrophilic fumed silica with a specific surface area of 200 m². 2 / g(EVONIK).
[0169] Glandosane: Artificial saliva
[0170] Oral films with the formulation in Table 3 were produced according to Example 2.
[0171] According to the formulation in Table 4, the oral film is characterized by its high flexibility and pleasant sensation ("oral feel"). Furthermore, oral films produced in this manner dissolve very quickly in the mouth, despite potentially high surface weight and considerable thickness. Due to the thin bubble walls, very gentle drying (e.g., 200 g / m³) is possible. 2 (Dry at 70℃ for 20 minutes).
[0172] Example 4:
[0173] Table 5:
[0174]
[0175] PVA 4-88: Polyvinyl alcohol
[0176] Flavoring: MANE Cherry M55394
[0177] The oral films formulated according to Table 5 are produced using mass production techniques known to those skilled in the art, such as stirring / mixing the contained components by means of a stirring motor and suitable stirring tools.
[0178] Gas is injected into the resulting material through agitation, such as using a foaming machine. The foaming material is then applied to the substrate at a constant thickness using appropriate equipment (roller applicator, scraper, application box, etc.).
[0179] All temperature-stable mesh materials can serve as coating substrates from which the dry film can be removed again. This can be ensured by selecting the material of the coating substrate (the different surface tensions between the foam and the substrate) or by applying a suitable debonding coating to the coating substrate using materials such as silicone or fluoropolymers. The process solvents or solvents contained therein are typically water or a mixture of water and an organic-aqueous miscible solvent, which are removed by drying.
[0180] The two laminates are then heated to 70°C and laminated together. Oral films can be supplied in appropriate sizes by cutting or punching holes in the two laminates thus obtained.
[0181] This two-layer oral membrane is characterized by its thickness and high load capacity. This process can be repeated frequently as needed, thereby obtaining multi-layer laminated membranes (e.g., three-layer or four-layer laminated membranes), or several laminated membranes can be laminated together in one step (e.g., heating three laminated membranes to 70°C and then laminating them together).
[0182] Example 5
[0183] Table 6:
[0184]
[0185] Similar to Example 2 or Example 3, oral films with the formulation according to Table 6 were produced.
[0186] Example 6
[0187] Table 7:
[0188] Formula 12 [wt%] Formula 13 [wt%] PVA 4-88 39.5 36.15 PVA 40-88 --- 36.15 (S)-Chloramine Hydrochloride 50.0 --- Sodium saccharin 1.0 1.0 Sucralose 2.0 2.0 Cherry flavor 3.0 --- glycerin 4.5 4.5 TRIS --- 20.0 FD&C Red 40 --- 0.2 face weight / size <![CDATA[193g / m 2 3.34cm 2 ]]> <![CDATA[160g / m 2 ]]> gas Nitrogen Nitrogen Process solvents water water
[0189] In each case, the oral film was produced according to the formulation in Table 7. The production process was similar to that of Example 1 or Example 2.
[0190] Oral membranes were dissolved individually in water or Glandosane (artificial saliva), and the pH of the solutions was measured. Alternatively, both membranes were dissolved together in water or Glandosane, and the pH of the solutions was measured (see Table 8).
[0191] Table 8:
[0192] pH value in water (2mL) pH value in Glandosane (2 mL) Ketamine OTF 5.85 5.11 TRIS OTF 9.65 8.91 Ketamine OTF+TRIS OTF 7.13 6.94
[0193] Example 7
[0194] Table 9:
[0195]
[0196] PVA 4-88: Polyvinyl alcohol
[0197] Flavoring: MANE Cherry M55394
[0198] Colorant: FD&C Red
[0199] Kollidon VA 64: Vinylpyrrolidone-vinyl acetate copolymer
[0200] The produced film consists of an active material layer, a buffer layer, and an adhesive layer, as shown below. These layers were prepared according to the descriptions in Examples 1 and 2, respectively. Their compositions are described in the corresponding tables.
[0201] Thus, a multilayer oral film with a structure of buffer layer-adhesive layer-active substance layer-adhesive layer-buffer layer was fabricated, as follows: The adhesive layer was laminated onto both sides of the ketamine laminate. After removing the carrier film, the TRIS buffer layer was then laminated onto both sides.
[0202] The result is a uniform foam composite material with good tactile properties and good solubility in terms of thickness.
[0203] pH measurement results show:
[0204] 3.34cm 2 OTF in 2 mL of water: pH = 8.07 (at 35.5°C).
[0205] The pH value of 2 mL of human saliva is: pH = 8.04 (at 36.3℃).
[0206] Example 8
[0207] Table 10:
[0208]
[0209] PVA 4-88: Polyvinyl alcohol
[0210] Flavoring: MANE Cherry M55394
[0211] Colorant: FD&C Red
[0212] Kollidon VA 64: Vinylpyrrolidone-vinyl acetate copolymer
[0213] Thin films comprising an active material layer, a buffer layer, and an adhesive layer were produced as described in Examples 1, 2, and 7, respectively. Their compositions are described in the corresponding tables.
[0214] Thus, a multilayer oral film with a buffer layer-adhesive layer-active substance layer structure was produced, as follows: An adhesive layer was laminated onto ketamine foam. After removing the carrier film of the adhesive layer, TRIS foam was laminated on top.
[0215] The result is a uniform foam composite material with good tactile properties and good solubility in terms of thickness.
[0216] pH measurements showed that 3.34 cm² of OTF in 2 ml of water resulted in pH = 7.97 (at 36.3°C).
[0217] Example 9
[0218] Table 11
[0219]
[0220] PVA 4-88: Polyvinyl alcohol
[0221] Flavoring: MANE Cherry M55394
[0222] Colorant: FD&C Red
[0223] Kollidon VA 64: Vinylpyrrolidone-vinyl acetate copolymer
[0224] Thin films comprising an active material layer, a buffer layer, and an adhesive layer were produced as described in Examples 1, 2, and 7, respectively. Their compositions are described in the corresponding tables.
[0225] Thus, a multilayer oral film with a buffer layer-adhesive layer-active substance layer structure was produced, as follows: An adhesive layer was laminated onto ketamine foam. After removing the carrier film of the adhesive layer, TRIS foam was laminated onto it.
[0226] The result is a uniform foam composite material with good tactile properties and good solubility in terms of thickness.
[0227] Example 10
[0228] Table 12
[0229]
[0230] PVA 4-88: Polyvinyl alcohol
[0231] Flavoring: MANE Cherry M55394
[0232] Colorant: FD&C Red
[0233] Kollidon VA 64: Vinylpyrrolidone-vinyl acetate copolymer
[0234] Films comprising an active material layer, a buffer layer, and an adhesive layer were produced as described in Examples 1, 2, and 7, respectively, although the foaming step was omitted. Their composition is described in the corresponding tables.
[0235] Thus, a multilayer oral film with a buffer layer-adhesive layer-active substance layer structure was produced, as follows: An adhesive layer was laminated onto ketamine foam. After removing the carrier film of the adhesive layer, TRIS foam was laminated onto it.
[0236] The result is a uniform foam composite material with good tactile properties and good solubility in terms of thickness.
[0237] pH measurements showed that 3.34 square centimeters of OTF in 2 milliliters of water resulted in pH = 6.33 (at 32°C).
[0238] Example 11
[0239] Table 13:
[0240]
[0241] PVA 4-88: Polyvinyl alcohol
[0242] Flavoring: MANE Cherry M55394
[0243] Colorant: FD&C Red
[0244] Thin films comprising an active material layer, a buffer layer, and an adhesive layer were produced as described in Examples 1, 2, and 7, respectively. The compositions are described in the corresponding tables.
[0245] Thus, a multilayer oral film with a buffer layer-adhesive layer-active substance layer structure was produced, as follows: An adhesive layer was laminated onto ketamine foam. After removing the carrier film of the adhesive layer, TRIS foam was laminated onto it.
[0246] The result is a uniform foam composite material with good tactile properties and good solubility in terms of thickness.
[0247] Example 12
[0248] Table 14:
[0249]
[0250]
[0251] PVA 4-88: Polyvinyl alcohol
[0252] Flavoring: MANE Cherry M55394
[0253] Oral films having the formulation according to Table 14 were produced in accordance with the descriptions in Examples 1, 2 and 7.
[0254] Oral films with formulations according to Table 14 exhibit the following disadvantages:
[0255] It forms lumps and inhomogeneities in the material. The material cannot diffuse uniformly and is therefore unsuitable for film production. PVA, as the matrix polymer, is incompatible with the salt / buffer solutions listed in Table 14.
[0256] Example 13
[0257] Table 15:
[0258]
[0259]
[0260] Oral films having the formulation according to Table 15 were produced in accordance with the descriptions in Examples 1, 2 and 7.
[0261] The oral films formulated according to Table 15 exhibited the undesirable properties listed in Table 15.
[0262] An aqueous polymer dispersion (Smart Seal) is provided, and plasticizers, flavoring agents, and surfactants are added sequentially. Then, a second polymer is added. Finally, a buffer salt is stirred in.
[0263] The material was foamed, coated, and dried using conventional methods.
[0264] Example 14
[0265] Apply formula 2 and formula 12 together (two separate OTFs, each 3.34 square centimeters of OTF):
[0266] At 36.5℃, the pH value of 2 mL of water is: pH = 7.15.
[0267] Apply formula 5 and formula 12 together (two separate OTFs, each 3.34 square centimeters of OTF):
[0268] Regarding water:
[0269] At 21°C, the pH value of 2 ml of water in Formula 12 is: pH = 5.85.
[0270] At 21°C, the pH value of 2 ml of water in Formula 5 is: pH = 9.65.
[0271] At 21℃, the pH value of 2mL of water in Formula 12 + Formula 5 is: pH = 7.13.
[0272] For Glandosane (artificial saliva):
[0273] At 21°C, the pH value of 2 mL of Glandosane formulation 12 is: pH = 5.33.
[0274] At 21°C, the pH value of 2 mL of Glandosane formulation 5 is: pH = 8.91.
[0275] At 21°C, the pH value of 2 mL of Glandosane formulation 12 + formulation 5 is: pH = 6.94.
[0276] Apply formula 7 and formula 12 together (two separate OTFs, each 3.34 square centimeters of OTF):
[0277] Regarding water:
[0278] At 21°C, the pH value of 2 ml of water in Formula 12 is: pH = 5.85.
[0279] At 22°C, the pH value of 2 ml of water in Formula 7 is: pH = 9.61.
[0280] At 22°C, the pH value of 2 ml of water in Formula 12 + Formula 7 is: pH = 7.67.
[0281] For Glandosane (artificial saliva):
[0282] At 21°C, the pH value of 2 mL of Glandosane formulation 12 is: pH = 5.33.
[0283] At 21°C, the pH value of 2 mL of Glandosane formulation 7 is: pH = 9.01.
[0284] At 21°C, the pH value of 2 mL of Glandosane formulation 12 + formulation 7 is: pH = 7.24. Example 15
[0285] Apply formulations 13 and 26 together (Formula 13 OTF 2.27cm). 2 OTF and 2.27cm 2 Formula 26):
[0286] Ingredients: Dextromethorphan OTF: Formula 26 is provided in Table 16.
[0287] Table 16
[0288] Material Formula 26 [wt%] Dextromethorphan 43.78% PVA 4-88 38.00% Sodium saccharin 1.00% Sucralose 2.00% glycerin 4.54% Flavor 6.00% Amberlite IRP64 4.48% FD&C Red 40 0.20% Trometro (TRIS) -- solvent purified water surface weight <![CDATA[188g / cm 2 ]]>
[0289] As described in Examples 1, 2 and 7, oral films having the formulation according to Table 16 were produced.
[0290] pH measurement showed that the pH value of 2 ml of water at 35℃ was pH = 7.63.
[0291] Example 16
[0292] Apply formula 13 and formula 27 together (formula 13 OTF 2.27cm). 2 OTF and 2.27cm 2 Formula 27):
[0293] Table 17 shows the formulation 27 for the ingredient paracetamol (acetaminophen) OTF.
[0294] Table 17
[0295] Material Formula 27 [wt%] Acetaminophen 20.00% PVA 4-88 72.50% Sodium saccharin 0.50% Sucralose 1.00% glycerin 4.50% Flavor 1.50% Trometro (TRIS) -- solvent purified water surface weight <![CDATA[103g / cm 2 ]]>
[0296] As described in Examples 1, 2 and 7, oral films having the formulation according to Table 17 were produced.
[0297] pH measurement showed that the pH value of 2 ml of water at 33℃ was pH = 8.17.
[0298] Example 18
[0299] Formula 13 OTF 2.72cm 2 OTF and commercial BEMA fentanyl OTF (strength 200 μg) were administered together:
[0300] pH measurement showed that the pH value of 2 ml of water at 22℃ was pH = 8.67.
[0301] Example 19
[0302] The effect of pH on the permeability of protonable / deprotonable surfactants was determined. Adjusting the pH using a buffered OTF can reduce inter-individual pH differences and bring the pH into the optimal range for permeability. Multilayered OTFs can influence the release profile by increasing disintegration / dissolution time.
[0303] Ketamine OTF containing buffering agents has significantly better permeability than ketamine hydrochloride (without OTF) (more than 18 times higher).
[0304] Results summary in Figure 3 middle.
Claims
1. An oral film comprising at least one layer, said layer containing at least one polyvinyl alcohol and tris(hydroxymethyl)aminomethane, said tris(hydroxymethyl)aminomethane being in an amount of 15 to 70% by weight, based on the total weight of said at least one layer, characterized in that, The amount of polyvinyl alcohol in the at least one layer is 20 to 90 wt%, and the total weight ratio of the polyvinyl alcohol to the tris(hydroxymethyl)aminomethane is less than or equal to 100 wt% based on the total weight of the at least one layer.
2. The oral film according to claim 1, characterized in that, The amount of the tris(hydroxymethyl)aminomethane in the at least one layer is 25 to 55% by weight, based on the total weight of the at least one layer.
3. The oral film according to claim 1, characterized in that, The at least one layer comprises at least one pharmaceutically active substance, characterized in that the at least one pharmaceutically active substance includes ketamine or a pharmaceutically acceptable salt thereof.
4. The oral film according to claim 3, characterized in that, The at least one pharmaceutically active substance includes (S)-ketamine or a pharmaceutically acceptable salt thereof.
5. The oral film according to claim 1, characterized in that, The oral film has at least one additional layer, which contains at least one matrix polymer and at least one pharmaceutically active substance.
6. The oral film according to claim 5, characterized in that, The at least one polymer is selected from the group consisting of: starch, dextrin, polyacrylic acid, polyacrylate, polyvinylpyrrolidone, vinylpyrrolidone / vinyl acetate copolymer, polyvinyl alcohol, polyacrylamide, polyethylene glycol, gelatin, collagen, alginate, pectin, pullulan, astragalus gum, chitosan, alginic acid, arabinogalactan, galactomannan, agar, agarose, carrageenan, natural gum, carboxymethyl cellulose, hydroxypropyl cellulose, hydroxyethyl cellulose, hydroxypropyl methyl cellulose, hydroxypropyl ethyl cellulose, sodium carboxymethyl cellulose, ethyl or propyl cellulose.
7. The oral film according to claim 5, characterized in that, The at least one pharmaceutically active substance includes ketamine or a pharmaceutically acceptable salt thereof.
8. The oral film according to claim 7, characterized in that, The at least one pharmaceutically active substance includes (S)-ketamine or a pharmaceutically acceptable salt thereof.
9. The oral film according to claim 1, characterized in that, At least one layer containing at least one polyvinyl alcohol and tris(hydroxymethyl)aminomethane exists in the form of a solidified foam with cavities.
10. The oral film according to claim 1, characterized in that, At least one other layer containing at least one matrix polymer and at least one pharmaceutically active substance exists in the form of a solidified foam with cavities.
11. The oral film according to claim 9 or 10, characterized in that, The cavities are isolated from each other and exist in the form of bubbles, with each cavity filled with gas.
12. The oral film according to claim 11, characterized in that, The gas includes an inert gas or air.
13. The oral film according to claim 12, characterized in that, The inert gas includes nitrogen, carbon dioxide, helium, or a mixture of at least two of these gases.
14. The oral film according to claim 9 or 10, characterized in that, The cavities are interconnected and form a channel system that penetrates the matrix layer.
15. The oral film according to claim 9 or 10, characterized in that, The cavity occupies 5% to 98% of the volume, based on the total volume of each layer.
16. The oral film according to claim 9 or 10, characterized in that, The cavity occupies 50 to 80% of the volume, based on the total volume of each layer.
17. The oral film according to claim 5, characterized in that, At least one layer comprising at least one polyvinyl alcohol and tris(hydroxymethyl)aminomethane and at least one other layer comprising at least one matrix polymer and at least one pharmaceutically active substance are directly laminated to each other or bonded to each other by an adhesive layer or a release layer located in between.
18. The oral film according to claim 1, characterized in that, The oral membrane produces a pH value of 6 to 9 at 37°C in the patient's mouth.
19. The oral film according to claim 1, characterized in that, The oral membrane produces a pH value of 6 to 8 at 37°C in the patient's mouth.
20. The oral film according to claim 1, wherein the film is used as a medicine.
Citation Information
Patent Citations
Multi-layer oral thin film
CN111655242A
Permeant delivery system and methods for use thereof
WO2009124096A1
